Kye Young Lee

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Yi‐Long Wu, Caicun Zhou, Chengping Hu et al. · The Lancet Oncology · 2014 · 2K citations

Lux-lung 6, Medicine, Randomised Phase 3 +8

Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer

Yi‐Long Wu, Masahiro Tsuboi, Jie He et al. · New England Journal of Medicine · 2020 · 1.7K citations · Full text

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

James Chih‐Hsin Yang, Yi‐Long Wu, Martin Schüler et al. · The Lancet Oncology · 2015 · 1.6K citations

Lux-lung 3, Lux-lung 6, Medicine +9

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial

Roy S. Herbst, Yi‐Long Wu, Thomas John et al. · Journal of Clinical Oncology · 2023 · 350 citations · Full text

PG490 (Triptolide) Cooperates with Tumor Necrosis Factor-α to Induce Apoptosis in Tumor Cells

Kye Young Lee, Wenteh Chang, Daoming Qiu et al. · Journal of Biological Chemistry · 1999 · 184 citations · Full text